Efficacy of cyclosporine 0.05% in patients with dry eye syndrome

Jitender Phogat, Ritesh Verma, Manisha Rathi, Sumit Sachdeva, Latika Pandey


Background: An even and smooth ocular surface is vital for the functioning and comfort of the eyes. Dry eye is a group of disorders of the tear film which is due to either decreased production or increased evaporation and is associated with symptoms of ocular discomfort. Smoking and drugs have been suggested as risk factors in various studies. Cyclosporine has been shown to reduce the cell-mediated inflammatory reactions associated with the inflammatory ocular surface disease.

Methods: 50 eyes of 25 patients suffering from dry-eye syndrome were included in this study. Three major ocular symptoms of dry eye i.e., ocular pain, burning, and foreign body sensation were studied in this study. Each symptom was given a score from 0 to 1 so that the ocular symptoms were given a score from 0 to 3.

Results: There was a significant reduction in ocular symptoms score (OSS) 2.25 before treatment to 0.6 after 3 months of treatment (p=0.01). In addition, the Schirmer's paper test scores improved from 1.23 mm to 5.91 mm, which is significantly different (p=0.001). The tear film breakup time also improved from 5.49s to 9.86s.

Conclusions: Cyclosporine 0.05% has been established to be effective and safe in our study.


Cyclosporine, Dry eye, Tear film

Full Text:



The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75–92.

Javadi MA, Feizi S. Dry eye syndrome. J Ophthalmic Vis Res. 2011;6(3):192–8.

Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):108–52.

Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009; 3 :405-12.

Johnson ME, Murphy PJ. Changes in the tear film and ocular surface from dry eye syndrome. Prog Retin Eye Res 2004;23:449-74.

Chen Q, Li X, He W, Zhang H, Gao A, Cheng Y, et al. The epitope study of alpha-fodrin autoantibody in primary Sjögren's syndrome. Clin Exp Immunol. 2007;149:497-503.

Pflugfelder SC. Anti-inflammatory therapy for dry eye. Am J Ophthalmol. 2004;137:337-42.

Behrens A, Doyle JJ, Stern L. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25:900-7.

Rajpal RK, Digby D, D'Aversa G, Mah F, Hollander DA, Conway T. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review. J Ocul Pharmacol Ther. 2011;27:305-8.

Strong B, Farley W, Stern ME, Pflugfelder SC. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine kerato-conjunctivitis sicca. Cornea. 2005;24:80–5.

Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56:307–18.

Power WJ, Mullaney P, Farrell M, Collum LM. Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjogren's syndrome. Cornea. 1993;12:507–11.

Perry HD, Solomon R, Donnenfeld ED, Perry AR, Wittpenn JR, Greenman HE, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126:1046-50.

Byun YS, Rho CR, Cho K, Choi JA, Na KS, Joo CK. Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: a prospective, multicenter, open-label, surveillance study. Korean J Ophthalmol. 2011;25(6):369–74.

Salib GM, McDonald MB, Smolek M. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis. J Cataract Refract Surg. 2006;32:772-8.

Guzey M, Karaman SK, Satici A, Ozardali I, Sezer S, Bozkurt O. Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye. Clin Experiment Ophthalmol. 2009;37:541-9.